The report analyzes and forecasts the erythropoietin drugs market at global and regional levels. The market has been forecast based on volume (Tons) and value (US$ Mn) from 2019 to 2026. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level. For the region and all segments, the sales, revenue and their market share, growth rate are key research objects; we can research the manufacturers' sales, price, revenue, cost and gross profit and their changes. What's more, we will display the main consumers, raw material manufacturers, distributors, etc.
This report first introduces the background of erythropoietin drugs, including the definition, classification, application, industrial chain structure, industry overview, national policy and planning analysis of the industry, and the latest dynamic analysis. With regard to production bases and technologies, the research in this report covers the production time, base distribution, technical parameters, research and development trends, technology sources, and sources of raw materials of major erythropoietin drugs companies.
Regarding the analysis of the industry chain, the research of this report covers the raw materials and equipment of erythropoietin drugs upstream, downstream customers, marketing channels, industry development trends and investment strategy recommendations. The more specific analysis also includes the main application areas of erythropoietin drugs and consumption, major regions and consumption, major global producers, distributors, raw material suppliers, equipment providers and their contact information, industry chain relationship analysis.
The report comprises a detailed value chain analysis, which provides a comprehensive view of the global erythropoietin drugs market. The Porter’s Five Forces model has also been included to help understand the competitive landscape of the market. The study encompasses market attractiveness analysis, wherein various applications have been benchmarked based on their market size, growth rate, and general attractiveness.
The study provides a decisive view of the erythropoietin drugs market by segmenting it in terms of form and application. The segment has been analyzed based on the present and future trends. Regional segmentation includes the current and projected demand in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
The report provides size (in terms of volume and value) of erythropoietin drugs market for the base year 2018 and the forecast between 2019 and 2026. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.
Competitive Landscape
Market share analysis among the market players is analyzed to signify the contribution of these players in the market in terms of percentage share. All these factors will help the market players to decide about the business strategies and plans to strengthen their positions in the global market. Based on geography, the market has been analyzed for major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The study also covers detailed country analysis contributing majorly in the erythropoietin drugs market.
The report also profiles the major players in the market and provides various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Companies profiled in the erythropoietin drugs market report are Amgen Inc., Novartis AG, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Merck & Co., Inc., Johnson & Johnson, Wockhardt Ltd., Pfizer, Inc., Biocon Ltd., and Teva Pharmaceutical Industries Ltd. among others.
The Erythropoietin Drugs Market has been segmented as follows:
Research Methodology:
In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.
Primary research represents a bulk of research efforts, supplemented by extensive secondary research. Annual reports, press releases, and relevant documents of key players operating in various application areas have been reviewed for competition analysis and market understanding.
Secondary research also includes recent trends, technical writing, Internet sources, and statistical data from government websites, trade associations, and agencies. These have proved to be reliable, effective, and successful approaches for obtaining precise market data, capturing market participants’ insights, and recognizing business opportunities.
The study objectives of this report are:
Section 1 Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
Section 2 Assumptions and Research Methodology
Section 3 Executive Summary
Section 4 Market Overview
4.1. Introduction
4.1.1. Product Type Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.1.1. Increase number of patients suffering from anemic condition
4.3.1.2. Increasing number of patients suffering from cancer
4.3.1.3. Increasing number of patients suffering from chronic kidney disease
4.3.1.4. Patent Expirations of Leading Erythropoietin Drugs
4.3.1.5. Rising demand for improved and advanced erythropoietin drugs products
4.3.1.6. Reimbursement policies for patients
4.3.2. Restraints
4.3.2.1. Highly priced erythropoietin drugs resulting in minimal adoption
4.3.2.2. High side effects of erythropoietin drugs
4.3.3 Opportunities
4.4. Global Erythropoietin Drugs Market Forecast
4.5. Porter's Five Forces Analysis
4.6. Market Outlook
4.7. Challenges
4.7.1. Cancer Worldwide
4.7.2. Anaemia Worldwide
4.7.3. Chronic Kidney Disease Worldwide
4.7.4. Erythropoietin Pipeline Drugs
4.7.5. Global Price of Erythropoietin Products
4.7.6. Global Regulatory Status
4.8. Heat Map Analysis
4.9. Product Profiling for Leading Drugs
4.10. Epoetin alfa
4.11. Epoetin beta
4.12. Darbepoetin alfa
4.13. Others
Section 5 Global Erythropoietin Drugs Market Analysis, by Drug Class
5.1. Key Findings / Developments
5.2. Introduction & Definition
5.3. Global Erythropoietin Drugs Market Value Share Analysis, by Drug Class
5.4. Global Erythropoietin Drugs Market Forecast, by Drug Class
5.5. Global Erythropoietin Drugs Market Analysis, by Drug Class
5.5.1. Epoetin Alfa
5.5.2. Epoetin Beta
5.5.3. Darbepoetin Alfa
5.5.4. Others
5.6. Global Erythropoietin Drugs Market Attractiveness, by Drug Class
Section 6 Global Erythropoietin Drugs Market Analysis, by Drug Type
6.1. Key Findings / Developments
6.2. Introduction & Definition
6.3. Global Erythropoietin Drugs Market Value Share Analysis, by Drug Type
6.4. Global Erythropoietin Drugs Market Forecast, by Drug Type
6.5. Global Erythropoietin Drugs Market Analysis, by Drug Type
6.5.1. Biologics
6.5.2. Biosimilar
6.6. Global Erythropoietin Drugs Market Attractiveness, by Drug Type
Section 7 Global Erythropoietin Drugs Market Analysis, by Drug Type
7.1. Key Findings / Developments
7.2. Introduction & Definition
7.3. Global Erythropoietin Drugs Market Value Share Analysis, by Distribution Channel
7.4. Global Erythropoietin Drugs Market Forecast, by Distribution Channel
7.5. Global Erythropoietin Drugs Market Forecast, by Distribution Channel
7.5.1. Hospital Pharmacy
7.5.2. Retail Pharmacy
7.5.3. Online Pharmacy
7.6. Global Erythropoietin Drugs Market Attractiveness, by Distribution Channel
Section 8 Global Erythropoietin Drugs Market Analysis, by Drug Application
8.1. Key Findings / Developments
8.2. Introduction & Definition
8.3. Global Erythropoietin Drugs Market Value Share Analysis, by Drug Application
8.4. Global Erythropoietin Drugs Market Forecast, by Drug Application
8.5. Global Erythropoietin Drugs Market Analysis, by Drug Application
8.5.1. Cancer
8.5.2. Renal Disease
8.5.3. Hematology
8.5.3. Neurology
8.5.4. Others
8.6. Global Erythropoietin Drugs Market Attractiveness, by Drug Application
Section 9 Global Erythropoietin Drugs Market Analysis, by Region
9.1. Global Erythropoietin Drugs Market
9.2. Introduction
9.3. Global Erythropoietin Drugs Market Value Share Analysis, by Region
9.4. Global Erythropoietin Drugs Market Forecast, by Region
9.5. Global Erythropoietin Drugs Market Attractiveness, by Region
Section 10 North America Erythropoietin Drugs Market Analysis
10.1. Key Findings / Developments
10.2. North America Erythropoietin Drugs Market Overview
10.3. North America Erythropoietin Drugs Market Value Share Analysis, by Country
10.3.1. U.S.
10.3.2. Canada
10.4. North America Erythropoietin Drugs Market Forecast, by Country
10.5. North America Erythropoietin Drugs Market Value Share Analysis, by Drug Class
10.5.1. Epoetin Alfa
10.5.2. Epoetin Beta
10.5.3. Darbepoetin Alfa
10.5.4. Others
10.6. North America Erythropoietin Drugs Market Forecast, by Drug Class
10.7. North America Erythropoietin Drugs Market Value Share Analysis, by Distribution Channel
10.7.1. Hospital Pharmacy
10.7.2. Retail Pharmacy
10.7.3. Online Pharmacy
10.8. North America Erythropoietin Drugs Market Forecast, by Distribution Channel
10.9. North America Erythropoietin Drugs Market Value Share Analysis, by Drug Type
10.9.1. Biologics
10.9.2. Biosimilar
10.10. North America Erythropoietin Drugs Market Forecast, by Drug Type
10.11. North America Erythropoietin Drugs Market Value Share Analysis, by Drug Application
10.11.1. Cancer
10.11.2. Renal Disease
10.11.3. Hematology
10.11.4. Neurology
10.11.5. Others (Surgery, Wound healing, etc.)
10.12. North America Erythropoietin Drugs Market Forecast, by Drug Application
10.13. North America Erythropoietin Drugs Market Attractiveness Analysis
Section 11 Europe Erythropoietin Drugs Market Analysis
11.1 Key Findings / Developments
11.2. Europe Erythropoietin Drugs Market Overview
11.3. Europe Erythropoietin Drugs Market Value Share Analysis, by Country/Sub-region
11.3.1. Germany
11.3.2. U.K.
11.3.3. France
11.3.4. Italy
11.3.5. Spain
11.3.6. Rest of Europe
11.4. Europe Erythropoietin Drugs Market Forecast, by Country
11.5. Europe Erythropoietin Drugs Market Value Share Analysis, by Drug Class
11.5.1. Epoetin Alfa
11.5.2. Epoetin Beta
11.5.3. Darbepoetin Alfa
11.5.4. Others
11.6. Europe Erythropoietin Drugs Market Forecast, by Drug Class
11.7. Europe Erythropoietin Drugs Market Value Share Analysis, by Distribution Channel
11.7.1. Hospital Pharmacy
11.7.2. Retail Pharmacy
11.7.3. Online Pharmacy
11.8. Europe Erythropoietin Drugs Market Forecast, by Distribution Channel
11.9. Europe Erythropoietin Drugs Market Value Share Analysis, by Drug Type
11.9.1. Biologics
11.9.2. Biosimilar
11.10. Europe Erythropoietin Drugs Market Forecast, by Drug Type
11.11. Europe Erythropoietin Drugs Market Value Share Analysis, by Drug Application
11.11.1. Cancer
11.11.2. Renal Disease
11.11.3. Hematology
11.11.4. Neurology
11.11.5. Others (Surgery, Wound healing, etc.)
11.12. Europe Erythropoietin Drugs Market Forecast, by Drug Application
11.13. Europe Erythropoietin Drugs Market Attractiveness Analysis
Section 12 Asia Pacific Erythropoietin Drugs Market Analysis
12.1 Key Findings / Developments
12.2. Asia Pacific Erythropoietin Drugs Market Overview
12.3. Asia Pacific Erythropoietin Drugs Market Value Share Analysis, by Country/Sub-region
12.3.1. Japan
12.3.2. China
12.3.3. India
12.3.4. Australia & New Zealand
12.3.5. Rest of APAC
12.4. Asia Pacific Erythropoietin Drugs Market Forecast, by Country
12.5. Asia Pacific Erythropoietin Drugs Market Value Share Analysis, by Drug Class
12.5.1. Epoetin Alfa
12.5.2. Epoetin Beta
12.5.3. Darbepoetin Alfa
12.5.4. Others
12.6. Asia Pacific Erythropoietin Drugs Market Forecast, by Drug Class
12.7. Asia Pacific Erythropoietin Drugs Market Value Share Analysis, by Distribution Channel
12.7.1. Hospital Pharmacy
12.7.2. Retail Pharmacy
12.7.3. Online Pharmacy
12.8. Asia Pacific Erythropoietin Drugs Market Forecast, by Distribution Channel
12.9. Asia Pacific Erythropoietin Drugs Market Value Share Analysis, by Drug Type
12.9.1. Biologics
12.9.2. Biosimilar
12.10. Asia Pacific Erythropoietin Drugs Market Forecast, by Drug Type
12.11. Asia Pacific Erythropoietin Drugs Market Value Share Analysis, by Drug Application
12.11.1. Cancer
12.11.2. Renal Disease
12.11.3. Hematology
12.11.4. Neurology
12.11.5. Others (Surgery, Wound healing, etc.)
12.12. Asia Pacific Erythropoietin Drugs Market Forecast, by Drug Application
12.13. Asia Pacific Erythropoietin Drugs Market Attractiveness Analysis
Section 13 Asia Pacific Erythropoietin Drugs Market Analysis
13.1 Key Findings / Developments
13.2. Latin America Erythropoietin Drugs Market Overview
13.3. Latin America Erythropoietin Drugs Market Value Share Analysis, by Country/Sub-region
13.3.1. Brazil
13.3.2. Mexico
13.3.3. Rest of LA
13.4. Latin America Erythropoietin Drugs Market Forecast, by Country
13.5. Latin America Erythropoietin Drugs Market Value Share Analysis, by Drug Class
13.5.1. Epoetin Alfa
13.5.2. Epoetin Beta
13.5.3. Darbepoetin Alfa
13.5.4. Others
13.6. Latin America Erythropoietin Drugs Market Forecast, by Drug Class
13.7. Latin America Erythropoietin Drugs Market Value Share Analysis, by Distribution Channel
13.7.1. Hospital Pharmacy
13.7.2. Retail Pharmacy
13.7.3 Online Pharmacy
13.8. Latin America Erythropoietin Drugs Market Forecast, by Distribution Channel
13.9. Latin America Erythropoietin Drugs Market Value Share Analysis, by Drug Type
13.9.1. Biologics
13.9.2. Biosimilar
13.10. Latin America Erythropoietin Drugs Market Forecast, by Drug Type
13.11. Latin America Erythropoietin Drugs Market Value Share Analysis, by Drug Application
13.11.1. Cancer
13.11.2. Renal Disease
13.11.3. Hematology
13.11.4. Neurology
13.11.5. Others (Surgery, Wound healing, etc.)
13.12. Latin America Erythropoietin Drugs Market Forecast, by Drug Application
13.13. Latin America Erythropoietin Drugs Market Attractiveness Analysis
Section 14 Middle East & Africa Erythropoietin Drugs Market Analysis
14.1. Key Findings / Developments
14.2. Middle East & Africa Erythropoietin Drugs Market Overview
14.3. Middle East & Africa Erythropoietin Drugs Market Value Share Analysis, by Country/Sub-region
14.3.1. GCC Countries
14.3.2. South Africa
14.3.3. Israel
14.3.4. Rest of MEA
14.4. Middle East & Africa Erythropoietin Drugs Market Forecast, by Country
14.5. Middle East & Africa Erythropoietin Drugs Market Value Share Analysis, by Drug Class
14.5.1. Epoetin Alfa
14.5.2. Epoetin Beta
14.5.3. Darbepoetin Alfa
14.5.4. Others
14.6. Middle East & Africa Erythropoietin Drugs Market Forecast, by Drug Class
14.7. Middle East & Africa Erythropoietin Drugs Market Value Share Analysis, by Distribution Channel
14.7.1. Hospital Pharmacy
14.7.2. Retail Pharmacy
14.7.3 Online Pharmacy
14.8. Middle East & Africa Erythropoietin Drugs Market Forecast, by Distribution Channel
14.9. Middle East & Africa Erythropoietin Drugs Market Value Share Analysis, by Drug Type
14.9.1. Biologics
14.9.2. Biosimilar
14.10. Middle East & Africa Erythropoietin Drugs Market Forecast, by Drug Type
14.11. Middle East & Africa Erythropoietin Drugs Market Value Share Analysis, by Drug Application
14.11.1. Cancer
14.11.2. Renal Disease
14.11.3. Hematology
14.11.4. Neurology
14.11.5. Others (Surgery, Wound healing, etc.)
14.12. Middle East & Africa Erythropoietin Drugs Market Forecast, by Drug Application
14.13. Middle East & Africa Erythropoietin Drugs Market Attractiveness Analysis
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers